(Press-News.org) CAMBRIDGE, MA -- To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.
A team of researchers from MIT, Harvard University and Boston Children's Hospital has now added a new element to tissue scaffolds — electronic sensors. These sensors, made of silicon nanowires, could be used to monitor electrical activity in the tissue surrounding the scaffold, control drug release or screen drug candidates for their effects on the beating of heart tissue.
The research, published online Aug. 26 in Nature Materials, could also pave the way for development of tissue-engineered hearts, says Robert Langer, the David H. Koch Institute Professor at MIT and a senior author of the paper.
"We are very excited about this study," Langer says. "It brings us one step closer to someday creating a tissue-engineered heart, and it shows how novel nanomaterials can play a role in this field."
Lead authors of the paper are Bozhi Tian, a former postdoc at MIT and Children's Hospital; Jia Liu, a Harvard graduate student; and Tal Dvir, a former MIT postdoc. Other senior authors are Daniel Kohane, director of the Laboratory for Biomaterials and Drug Delivery at Children's Hospital, and Charles Lieber, a Harvard professor of chemistry.
A 3-D system
Until now, the only cellular platforms that incorporated electronic sensors consisted of flat layers of cells grown on planar metal electrodes or transistors. Those two-dimensional systems do not accurately replicate natural tissue, so the research team set out to design a 3-D scaffold that could monitor electrical activity, allowing them to see how cells inside the structure would respond to specific drugs.
The researchers built their new scaffold out of epoxy, a nontoxic material that can take on a porous, 3-D structure. Silicon nanowires embedded in the scaffold carry electrical signals to and from cells grown within the structure.
"The scaffold is not just a mechanical support for cells, it contains multiple sensors. We seed cells into the scaffold and eventually it becomes a 3-D engineered tissue," Tian says.
The team chose silicon nanowires as its electronic sensors because they are small, stable, can be safely implanted into living tissue, and are more electrically sensitive than metal electrodes. The nanowires, which range in diameter from 30 to 80 nanometers (about 1,000 times smaller than that of a human hair), can detect voltages less than one-thousandth of a watt, which is the level of electricity that might be seen in a cell.
Monitoring cell behavior
In the Nature Materials study, the researchers used their scaffolds to grow cardiac, neural and muscle tissue. Using the engineered cardiac tissue, the researchers were able to monitor cells' response to noradrenalin, a stimulant that typically increases heart rate.
The team also grew blood vessels with embedded electronic sensors and showed they could be used to measure pH changes within and outside the vessels. Such implantable devices could allow doctors to monitor inflammation or other biochemical events in patients who receive the implants. Ultimately, the researchers would like to engineer tissues that can not only sense an electrical or chemical event, but also respond to it appropriately — for example, by releasing a drug.
"It could be a closed feedback loop, much as our autonomic nervous system is," Kohane says. "The nervous system senses changes in some part of the body and sends a message to the central nervous system, which then sends a message back to take corrective action."
The team is now further studying the mechanical properties of the scaffolds and making plans to test them in animals.
###
The research was funded by the National Institutes of Health, the McKnight Foundation and Boston Children's Hospital.
Written by Anne Trafton, MIT News Office
END
Munich, Germany – A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people. However, there is still only limited evidence that the intraaortic balloon pump (IABP), one of the oldest medical devices in cardiology, is actually beneficial for the patient. Only a few registry studies and clinical trials have shown that the IABP can improve blood pressure and the perfusion of the coronary arteries.
Based on these studies, international ...
MBL, WOODS HOLE, MA-- Squid's colorful, changeable skin enables the animal--and their close relatives, cuttlefish and octopus--to display extraordinary camouflage, the speed and diversity of which is unmatched in the animal kingdom.
But how squid control their skin's iridescence, or light-reflecting property, which is responsible for the animal's sparkly rainbow of color, has been unknown.
In a new study, MBL (Marine Biological Laboratory) researchers Paloma Gonzalez Bellido and Trevor Wardill and their colleagues report that nerves in squid skin control the animal's ...
Munich, Germany – Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the PROTECT study described here today at ESC Congress 2012.
Presenting the results, Professor William Wijns from the Cardiovascular Center in Aalst, Belgium, said that the decline in rates of stent thrombosis seen recently and in the PROTECT (Patient Related OuTcomes with Endeavor versus Cypher Stenting) study was probably explained by several factors, including "improvements in patient selection, procedural ...
Munich, Germany – Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.
Even after adjusting for the use of primary percutaneous coronary intervention (PCI) and reperfusion therapy, there still remained a substantial decrease in early mortality rate (>60%), underlining the importance ...
Munich, Germany – The German Aortic Valve Registry (GARY) was started in July 2010 and is the only registry so far to include both transcatheter aortic valve implantation (TAVI) and conventional aortic valve replacements and repair.(1) The intention is to deliver a complete picture of current and future practice of treating aortic valve disease and to deliver reliable data on the short and long-term outcome of different treatment strategies. This specifically includes data about quality of life before and after treatment besides numerous medical variables.
Participation ...
Munich, Germany –The percutaneous catheter-based treatment of mitral regurgitation with the MitraClip system improves symptoms and cardiac function at one-year, according to results of a prospective observational study presented here today at ESC Congress 2012.
ACCESS-EUROPE (ACCESS-EU) was a multicentre study of the MitraClip system in a commercial setting in 567 patients enrolled at 14 European sites, the largest group of patients evaluated to date. The results were presented by the study's co-principal investigator Professor Wolfgang Schillinger of the Universitätsmedizin ...
Munich, Germany – A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
However, while insulin glargine did significantly reduce the secondary outcomes of the study ...
Scientists at the Oswaldo Cruz Foundation and Federal University of Minas Gerais, led by Dr. Andréa Teixeira-Carvalho and Dr. Mônica Cristina de Oliveira, have developed and characterized a circulating and pH-sensitive liposome containing cisplatin (SpHL-CDDP) aiming to promote the release of cisplatin near the tumor as well as decreasing toxicity. The development of analog drugs and new formulations are current strategies for increasing the effectiveness and safety of cisplatin as an anti-peritoneal carcinomatosis drug. The results, which appear in the August 2012 issue ...
Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center's Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University.
Led by Cheryl Thompson, PhD, the study is the first-of-its-kind to show an association between insufficient sleep and biologically more aggressive tumors as well as likelihood of cancer recurrence. The research team analyzed medical records and survey ...
ROCHESTER, Minn. -- People who are of normal weight but have fat concentrated in their bellies have a higher death risk than those who are obese, according to Mayo Clinic research presented today at the European Society of Cardiology Congress in Munich. Those studied who had a normal body mass index but central obesity -- a high waist-to-hip ratio -- had the highest cardiovascular death risk and the highest death risk from all causes, the analysis found.
"We knew from previous research that central obesity is bad, but what is new in this research is that the distribution ...